Status:
COMPLETED
Drug Interaction Study Between AZD3480 and Cytochrome P450
Lead Sponsor:
AstraZeneca
Conditions:
Metabolism
Alzheimer's Disease
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaluate if AZD3480 inhibits Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity.
Eligibility Criteria
Inclusion
- Provision of signed written informed consent
- Clinically normal physical findings and laboratory values
Exclusion
- Clinically significant illness or clinically relevant trauma within three weeks before the first dose
- History of clinically significant disease
- Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00692510
Start Date
November 1 2007
End Date
September 1 2008
Last Update
November 26 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Uppsala, Sweden